196 related articles for article (PubMed ID: 28338112)
21. Association of PNPLA3 rs738409 polymorphism with liver steatosis but not with cirrhosis in patients with HBV infection: Systematic review with meta-analysis.
Ghalamkari S; Sharafi H; Alavian SM
J Gene Med; 2018 Jan; 20(1):. PubMed ID: 29218813
[TBL] [Abstract][Full Text] [Related]
22. PNPLA3 risk allele is associated with risk of hepatocellular carcinoma but not decompensation in compensated cirrhosis.
Urias E; Tedesco NR; Burkholder DA; Moran IJ; Miller MJ; Jasty VSJ; Patil S; Zoellner S; Wijarnpreecha K; Chen VL
Hepatol Commun; 2024 Jun; 8(6):. PubMed ID: 38780253
[TBL] [Abstract][Full Text] [Related]
23. Combination of PNPLA3 and TLL1 polymorphism can predict advanced fibrosis in Japanese patients with nonalcoholic fatty liver disease.
Seko Y; Yamaguchi K; Mizuno N; Okuda K; Takemura M; Taketani H; Hara T; Umemura A; Nishikawa T; Moriguchi M; Yasui K; Kamaguchi M; Nishioji K; Mochizuki N; Kobayashi M; Mori K; Tanaka S; Matsuura K; Tanaka Y; Itoh Y
J Gastroenterol; 2018 Mar; 53(3):438-448. PubMed ID: 28744823
[TBL] [Abstract][Full Text] [Related]
24. PNPLA3 and TM6SF2 variants as risk factors of hepatocellular carcinoma across various etiologies and severity of underlying liver diseases.
Yang J; Trépo E; Nahon P; Cao Q; Moreno C; Letouzé E; Imbeaud S; Gustot T; Deviere J; Debette S; Amouyel P; Bioulac-Sage P; Calderaro J; Ganne-Carrié N; Laurent A; Blanc JF; Guyot E; Sutton A; Ziol M; Zucman-Rossi J; Nault JC
Int J Cancer; 2019 Feb; 144(3):533-544. PubMed ID: 30289982
[TBL] [Abstract][Full Text] [Related]
25. Genetic determinants of steatosis and fibrosis progression in paediatric non-alcoholic fatty liver disease.
Hudert CA; Selinski S; Rudolph B; Bläker H; Loddenkemper C; Thielhorn R; Berndt N; Golka K; Cadenas C; Reinders J; Henning S; Bufler P; Jansen PLM; Holzhütter HG; Meierhofer D; Hengstler JG; Wiegand S
Liver Int; 2019 Mar; 39(3):540-556. PubMed ID: 30444569
[TBL] [Abstract][Full Text] [Related]
26. MERTK rs4374383 polymorphism affects the severity of fibrosis in non-alcoholic fatty liver disease.
Petta S; Valenti L; Marra F; Grimaudo S; Tripodo C; Bugianesi E; Cammà C; Cappon A; Di Marco V; Di Maira G; Dongiovanni P; Rametta R; Gulino A; Mozzi E; Orlando E; Maggioni M; Pipitone RM; Fargion S; Craxì A
J Hepatol; 2016 Mar; 64(3):682-90. PubMed ID: 26596542
[TBL] [Abstract][Full Text] [Related]
27. PNPLA3 rs738409, hepatocellular carcinoma occurrence and risk model prediction in patients with cirrhosis.
Guyot E; Sutton A; Rufat P; Laguillier C; Mansouri A; Moreau R; Ganne-Carrié N; Beaugrand M; Charnaux N; Trinchet JC; Nahon P
J Hepatol; 2013 Feb; 58(2):312-8. PubMed ID: 23069476
[TBL] [Abstract][Full Text] [Related]
28. The PNPLA3 rs738409 GG genotype is associated with poorer prognosis in 239 patients with autoimmune hepatitis.
Mederacke YS; Kirstein MM; Großhennig A; Marhenke S; Metzler F; Manns MP; Vogel A; Mederacke I
Aliment Pharmacol Ther; 2020 Jun; 51(11):1160-1168. PubMed ID: 32323349
[TBL] [Abstract][Full Text] [Related]
29. The PNPLA3 rs738409 C > G polymorphism is associated with the risk of progression to cirrhosis in NAFLD patients.
Vespasiani-Gentilucci U; Gallo P; Porcari A; Carotti S; Galati G; Piccioni L; De Vincentis A; Dell'Unto C; Vorini F; Morini S; Riva E; Picardi A
Scand J Gastroenterol; 2016 Aug; 51(8):967-73. PubMed ID: 27150500
[TBL] [Abstract][Full Text] [Related]
30. Proprotein convertase 7 rs236918 associated with liver fibrosis in Italian patients with HFE-related hemochromatosis.
Pelucchi S; Galimberti S; Greni F; Rametta R; Mariani R; Pelloni I; Girelli D; Busti F; Ravasi G; Valsecchi MG; Valenti L; Piperno A
J Gastroenterol Hepatol; 2016 Jul; 31(7):1342-8. PubMed ID: 26868056
[TBL] [Abstract][Full Text] [Related]
31. Study of CXCL9-11 gene polymorphisms in liver fibrosis among patients with chronic hepatitis C.
Magri MC; Alvarez MSM; Iogi AA; Alves GM; Manchiero C; Dantas BP; Prata TVG; Nunes AKDS; Tengan FM
Pathog Dis; 2021 Mar; 79(3):. PubMed ID: 33476381
[TBL] [Abstract][Full Text] [Related]
32. The PNPLA3 Genetic Variant rs738409 Influences the Progression to Cirrhosis in HIV/Hepatitis C Virus Coinfected Patients.
Núñez-Torres R; Macías J; Mancebo M; Frías M; Dolci G; Téllez F; Merino D; Merchante N; Gómez-Mateos J; Guaraldi G; Rivero-Juárez A; Pineda JA; Real LM;
PLoS One; 2016; 11(12):e0168265. PubMed ID: 27973562
[TBL] [Abstract][Full Text] [Related]
33. Common polymorphism in the PNPLA3/adiponutrin gene confers higher risk of cirrhosis and liver damage in alcoholic liver disease.
Trépo E; Gustot T; Degré D; Lemmers A; Verset L; Demetter P; Ouziel R; Quertinmont E; Vercruysse V; Amininejad L; Deltenre P; Le Moine O; Devière J; Franchimont D; Moreno C
J Hepatol; 2011 Oct; 55(4):906-12. PubMed ID: 21334404
[TBL] [Abstract][Full Text] [Related]
34. The association of nonalcoholic fatty liver disease with genetic polymorphisms: a multicenter study.
Uygun A; Ozturk K; Demirci H; Oztuna A; Eren F; Kozan S; Yilmaz Y; Kurt O; Turker T; Vatansever S; Alper E; Unsal B
Eur J Gastroenterol Hepatol; 2017 Apr; 29(4):441-447. PubMed ID: 28253210
[TBL] [Abstract][Full Text] [Related]
35. The role of PNPLA3 and TM6SF2 polymorphisms on liver fibrosis and metabolic abnormalities in Brazilian patients with chronic hepatitis C.
Oliveira AIN; Malta FM; Zitelli PMY; Salles APM; Gomes-Gouvea MS; Nastri ACS; Pinho JRR; Carrilho FJ; Oliveira CP; Mendes-Corrêa MC; Pessoa MG; Mazo DF
BMC Gastroenterol; 2021 Feb; 21(1):81. PubMed ID: 33622266
[TBL] [Abstract][Full Text] [Related]
36. PNPLA3 polymorphism influences liver fibrosis in unselected patients with type 2 diabetes.
Petit JM; Guiu B; Masson D; Duvillard L; Jooste V; Buffier P; Bouillet B; Brindisi MC; Robin I; Gambert P; Verges B; Cercueil JP; Hillon P
Liver Int; 2011 Oct; 31(9):1332-6. PubMed ID: 21745307
[TBL] [Abstract][Full Text] [Related]
37. Genetic variants in PNPLA3 and TM6SF2 predispose to the development of hepatocellular carcinoma in individuals with alcohol-related cirrhosis.
Stickel F; Buch S; Nischalke HD; Weiss KH; Gotthardt D; Fischer J; Rosendahl J; Marot A; Elamly M; Casper M; Lammert F; McQuillin A; Zopf S; Spengler U; Marhenke S; Kirstein MM; Vogel A; Eyer F; von Felden J; Wege H; Buch T; Schafmayer C; Braun F; Deltenre P; Berg T; Morgan MY; Hampe J
Am J Gastroenterol; 2018 Oct; 113(10):1475-1483. PubMed ID: 29535416
[TBL] [Abstract][Full Text] [Related]
38. Impact of common risk factors of fibrosis progression in chronic hepatitis C.
Rüeger S; Bochud PY; Dufour JF; Müllhaupt B; Semela D; Heim MH; Moradpour D; Cerny A; Malinverni R; Booth DR; Suppiah V; George J; Argiro L; Halfon P; Bourlière M; Talal AH; Jacobson IM; Patin E; Nalpas B; Poynard T; Pol S; Abel L; Kutalik Z; Negro F
Gut; 2015 Oct; 64(10):1605-15. PubMed ID: 25214320
[TBL] [Abstract][Full Text] [Related]
39. PNPLA3 and TM6SF2 genetic variants and hepatic fibrosis and cirrhosis in Pakistani chronic hepatitis C patients: a genetic association study.
Rauff B; Alzahrani B; Chudhary SA; Nasir B; Mahmood S; Bhinder MA; Faheem M; Amar A
BMC Gastroenterol; 2022 Aug; 22(1):401. PubMed ID: 36028802
[TBL] [Abstract][Full Text] [Related]
40. SERPINA1 and HSD17B13 Gene Variants in Patients with Liver Fibrosis and Cirrhosis.
Basyte-Bacevice V; Skieceviciene J; Valantiene I; Sumskiene J; Petrenkiene V; Kondrackiene J; Petrauskas D; Lammert F; Kupcinskas J
J Gastrointestin Liver Dis; 2019 Sep; 28(3):297-302. PubMed ID: 31517326
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
